Cargando…
Renal Cell Carcinoma Molecular Targets and Clinical Applications, Second Edition /
In the second edition of their critically acclaimed book, Ronald Bukowski, Robert Motzer, and Robert Figlin have thoroughly updated and expanded their survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. A panel of internationally renowned contri...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Totowa, NJ :
Humana Press : Imprint: Humana,
2009.
|
| Edición: | 2nd ed. 2009. |
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-1-59745-332-5 | ||
| 003 | DE-He213 | ||
| 005 | 20220119074530.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 100301s2009 xxu| s |||| 0|eng d | ||
| 020 | |a 9781597453325 |9 978-1-59745-332-5 | ||
| 024 | 7 | |a 10.1007/978-1-59745-332-5 |2 doi | |
| 050 | 4 | |a RC254-282 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Renal Cell Carcinoma |h [electronic resource] : |b Molecular Targets and Clinical Applications, Second Edition / |c edited by Ronald Bukowski, Robert A. Figlin, Robert Motzer. |
| 250 | |a 2nd ed. 2009. | ||
| 264 | 1 | |a Totowa, NJ : |b Humana Press : |b Imprint: Humana, |c 2009. | |
| 300 | |a XVIII, 506 p. 25 illus. in color. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | |a Targeted Therapy for Metastatic Renal Cell Carcinoma : Overview -- Molecular Genetics of Inherited Renal Cell Carcinoma: Identification of Targets in the Hereditary Syndromes -- Molecular Targets in Renal Tumors: Pathologic Assessment -- Therapeutic Results and Molecular Basis of Activity -- VHL and HIF in Clear Cell Carcinoma -- Molecular Abnormalities and Potential Clinical Applications -- Vascular Endothelial Growth Factor (VEGF): Biologic Aspects and Clinical Approaches -- VEGF and PDGF Receptors: Biologic Relevance and Clinical Approaches to Inhibition -- Sunitinib and Axitinib in Renal Cell Carcinoma -- Sorafenib in Renal Cell Carcinoma -- Additional Tyrosine Kinase Inhibitors in Renal Cell Carcinoma -- Integrin a5ß1 as a Novel Therapeutic Target in Renal Cell Carcinoma -- Carbonic Anydrase IX: Biological and Clinical Approaches -- Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma: Biologic and Clinical Studies -- Chemokines in Renal Cell Carcinoma : Implications for Tumor Angiogenesis and Metastasis -- PI3K/Akt/mTOR Pathway: A Growth Proliferation Pathway -- EGFR/HER2: Relevance in Renal Cell Carcinoma -- Proteosome - NFkB Signaling Pathway : Relevance in Renal Cell Carcinoma -- The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma -- Smac/DIABLO: A Proapoptotic Molecular Target in Renal Cell Carcinoma -- EpH2A: A Novel Target in Renal Cell Carcinoma -- Restoring Host Targeted Therapy for Metastatic Renal Cell Carcinoma : Overview -- Molecular Genetics of Inherited Renal Cell Carcinoma: Identification of Targets in the Hereditary Syndromes -- Molecular Targets in Renal Tumors: Pathologic Assessment -- Therapeutic Results and Molecular Basis of Activity -- VHL and HIF in Clear Cell Carcinoma -- Molecular Abnormalities and Potential Clinical Applications -- Vascular Endothelial Growth Factor (VEGF): Biologic Aspects and Clinical Approaches -- VEGF and PDGF Receptors: Biologic Relevance and Clinical Approaches to Inhibition -- Sunitinib and Axitinib in Renal Cell Carcinoma -- Sorafenib in Renal Cell Carcinoma -- Additional Tyrosine Kinase Inhibitors in Renal Cell Carcinoma -- Integrin a5ß1 as a Novel Therapeutic Target in Renal Cell Carcinoma -- Carbonic Anydrase IX: Biological and Clinical Approaches -- Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma: Biologic and Clinical Studies -- Chemokines in Renal Cell Carcinoma : Implications for Tumor Angiogenesis and Metastasis -- PI3K/Akt/mTOR Pathway: A Growth Proliferation Pathway -- EGFR/HER2: Relevance in Renal Cell Carcinoma -- Proteosome - NFkB Signaling Pathway : Relevance in Renal Cell Carcinoma -- The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma -- Smac/DIABLO: A Proapoptotic Molecular Target in Renal Cell Carcinoma -- EpH2A: A Novel Target in Renal Cell Carcinoma -- Restoring Host Immunity: How Corrgulatory Molecules are Changing the Approach to Management of Renal Cell Carcinoma -- The Role of Gangliosides in Renal Cell Carcinoma -- Tumor Necrosis Factor - Misnomer and Therapeutic Target -- Molecularly Targeted Staging Strategies in Renal Cell Carcinoma -- Adjuvant therapy for Renal Cell Carcinoma : Targeted Approaches. Immunity: How Coregulatory Molecules are Changing the Approach to Management of Renal Cell Carcinoma -- The Role of Gangliosides in Renal Cell Carcinoma -- Tumor Necrosis Factor - Misnomer and Therapeutic Target -- Molecularly Targeted Staging Strategies in Renal Cell Carcinoma -- Adjuvant therapy for Renal Cell Carcinoma : Targeted Approaches. | |
| 520 | |a In the second edition of their critically acclaimed book, Ronald Bukowski, Robert Motzer, and Robert Figlin have thoroughly updated and expanded their survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. A panel of internationally renowned contributors explores the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors. The discussion includes the specific biology of selected target molecules or receptors and the various agents that inhibit these targets, including full chapters devoted to drugs that selectively inhibit receptor tyrosine kinases, such as sunitinib and axitinib. Further attention is paid to leading-edge strategies that target and inhibit tumor associated angiogenesis and block the vascular endothelial growth factor pathway. Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Second Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by the pioneers of the field. | ||
| 650 | 0 | |a Oncology. | |
| 650 | 0 | |a Nuclear medicine. | |
| 650 | 1 | 4 | |a Oncology. |
| 650 | 2 | 4 | |a Nuclear Medicine. |
| 700 | 1 | |a Bukowski, Ronald. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Figlin, Robert A. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Motzer, Robert. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9781607614685 |
| 776 | 0 | 8 | |i Printed edition: |z 9781607612216 |
| 776 | 0 | 8 | |i Printed edition: |z 9781588297372 |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-1-59745-332-5 |z Texto Completo |
| 912 | |a ZDB-2-SME | ||
| 912 | |a ZDB-2-SXM | ||
| 950 | |a Medicine (SpringerNature-11650) | ||
| 950 | |a Medicine (R0) (SpringerNature-43714) | ||